Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004926:Escherichia coli / Q000201:enzymology; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D006967:Hypersensitivity; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged
D000970:Antineoplastic Agents; D001215:Asparaginase